Merck & Co. Inc. (MRK), a healthcare company, Wednesday announced that the FDA has accepted to review the Biologics License Application or BLA for its investigational ragweed pollen, Ambrosia artemisiifolia sublingual allergy immunotherapy tablet. Further, the company added on that the FDA had also accepted the BLA for its investigational Timothy grass pollen or Phleum pratense, sublingual allergy immunotherapy tablet. Merck expects the FDA's review for both to be completed in the first half of 2014.
The BLA for Merck's investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. Merck has partnered with ALK-Abello to develop its sublingual allergy immunotherapy tablets, timothy grass pollen and house dust mite in North America.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.